Objective: To study the short-term efficiency and safety of pemetrexed plus cisplatin concurrent radiotherapy for locally advanced non-squamous-non-small cell lung cancer.Methods: Sixty-eight cases of non-squamous-non-small-cell lung cancer were divided into the observation group and the control group randomly. The observation group were given pemetrexed plus cisplatin concurrent intensity modulated radiotherapy, while the control group were given etoposide plus cisplatin concurrent intensity modulated radiotherapy. Then all the patients received sequential chemotherapy following previous regimens and followed-up for 3 months. The short-term efficiency and safety was compared between the two groups. Results: Efficiency rate and disease control rate of the observation group were 76.47% and 94.12% respectively, higher than those of the control group(52.94% and 76.47%), the difference were statistically significant(P<0.05). The incidence of leukocytopenia and nausea and vomiting of the observation group were 85.29% and 58.82%, lower than those of the control group, with statistical difference(P<0.05). The incidence of decreased hemoglobin, thrombocytopenia and liver damage in the two groups were all below 50%, without statistical difference(P>0.05).Conclusion: The short-term efficiency and safety of pemetrexed plus cisplatin concurrent radiotherapy for locally advanced non-squamous-non-small cell lung cancer are certain, they can be selected as first-line regimen. |
[1] WANG Z.Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies[J].Int J Clin Exp Med,2014,7(11):3833-3842.
[2] YUN M,KIM E O,LEE D,et al.Melatoninsensitizes H1975 non-small cell lung cancer cells harboring a T790M-targetedepidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib[J].Cell Physiol Biochem,2014,34(3):865-872.
[3] 蒋军,黄荣,邓燕明,等.培美曲塞联合顺铂在局部晚期肺腺癌同步放化疗中的临床研究[J].国际医药卫生导报,2013,19(21):3268-3273.
[4] MOORCRAFT S Y.Introduction to clinical problems in Oncology[M]//MOORCRAFT S Y,LEE D,CUNNINGHAM D,et al.Clinical problems in oncology:A practical guide to management.New Jersey:Wiley-Blackwell,2014:1-12.
[5] 陈兰,范娟.治疗非小细胞肺癌的临床研究进展[J].西南军医,2014,16(3):325-327.
[6] AHN J S,AHN Y C,KIM J H,et al.Multinational randomized phase Ⅲ trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage Ⅲ non-small-cell lung cancer:KCSG-LU05-04[J].J Clin Oncol,2015,33(24):2660-2666.
[7] 李金凯,葛小林,王沛沛,等.利用4D锥形束CT研究肺癌放疗的靶区外放范围[J].东南大学学报:医学版,2015,34(4):609-612.
[8] 孟丽娟,王俊,刘福银,等.老年晚期非小细胞肺癌单药二线培美曲赛或多西他赛化疗的临床观察[J].实用老年医学,2010,24(1):66-68.
[9] HWANG K E,KIM Y S,HWANG Y R,et al.Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction[J].Int J Oncol,2014,45(4):1769-1777.
[10] 包桂红.培美曲塞单药或联合化疗治疗晚期复发性非小细胞肺癌60例分析[J].中国医药指南,2016,14(2):149.
[11] ZHENG Y,FANG W,DENG J,et al.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status[J].J Thorac Dis,2014,6(7):958-964.
[12] KIM Y H,NISHIMURA T,OZASA H.Phase Ⅱ study of pemetrexed and erlotinib in pretreated nonsquamous,non-small-cell lung cancer patients without an EGFR mutation[J].Chemotherapy,2014,59(6):414-419. |